SCHEMBL30135945

SCHEMBL30135945

CC(C)(C)OC(=O)NC1CCN(C(=O)CCN2CCN(c3ccc4c(c3)CN(C3CCC(=O)NC3=O)C4=O)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.45
CRBN Q96SW2 13/20 0.44
CSNK1A1 P48729 2/20 0.42
WIZ O95785 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
METAP2 P50579 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
DDB1 Q16531 2/20 0.41
GSPT1 P15170 1/20 0.41
IKZF3 Q9UKT9 1/20 0.41
IKZF1 Q13422 1/20 0.41
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
IRAK1 P51617 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135891 0.96 ESR1 (0.44) ESR1CRBNCSNK1A1WIZCHRM2
SCHEMBL31205730 0.89 CRBN (0.53) ESR1CRBNCSNK1A1WIZDDB1
SCHEMBL20231554 0.89 CRBN (0.53) ESR1CRBNCSNK1A1WIZDDB1
SCHEMBL26839717 0.88 CRBN (0.53) CRBNDDB1CCNCCDK8IRAK1
SCHEMBL20231967 0.85 CRBN (0.53) ESR1CRBNCSNK1A1WIZDDB1
SCHEMBL30493359 0.85 CRBN (0.53) ESR1CRBNCSNK1A1WIZDDB1
SCHEMBL30135731 0.85 CRBN (0.46) CRBNDDB1IKZF3IKZF1
SCHEMBL29260027 0.85 CRBN (0.46) CRBNDDB1IKZF3IKZF1
SCHEMBL20231921 0.84 CRBN (0.52) CRBNCSNK1A1WIZDDB1GSPT1
SCHEMBL20234923 0.84 CRBN (0.52) CRBNCSNK1A1WIZDDB1GSPT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 US disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 EP disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017442-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ESR1 2685/4885CRBN 2136/4885CSNK1A1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.